Abstract |
Manipulation of the hormone oestrogen has been used for decades to treat hormone-dependent breast cancer. Currently, aromatase inhibitors (AIs) are used as first-line therapy against early and metastatic breast cancer in post-menopausal women. Despite these advances, several patients eventually experience a relapse of breast cancer and declined clinical response to treatment. As per recent findings, steroid sulfatase (STS) has emerged as a novel therapy target. This review aims at summarising the emerging field of STS inhibitor development and highlighting current findings from pre-clinical and clinical trials. The recently-developed dual-targeting compounds, such as dual aromatase- sulfatase inhibitors (DASI), have shown encouraging preclinical results and represent important new treatments for hormone-dependent breast cancer.
|
Authors | Hassan Sadozai |
Journal | JPMA. The Journal of the Pakistan Medical Association
(J Pak Med Assoc)
Vol. 63
Issue 4
Pg. 509-15
(Apr 2013)
ISSN: 0030-9982 [Print] Pakistan |
PMID | 23905452
(Publication Type: Journal Article, Review)
|
Chemical References |
- Aromatase Inhibitors
- Azasteroids
- Coumarins
- Enzyme Inhibitors
- Estrogens
- STX 213
- Sulfonamides
- Sulfonic Acids
- irosustat
- Steryl-Sulfatase
|
Topics |
- Aromatase Inhibitors
(therapeutic use)
- Azasteroids
(therapeutic use)
- Breast Neoplasms
(drug therapy, enzymology, metabolism)
- Coumarins
(therapeutic use)
- Drug Discovery
- Enzyme Inhibitors
(therapeutic use)
- Estrogens
(biosynthesis)
- Female
- Humans
- Steryl-Sulfatase
(antagonists & inhibitors)
- Sulfonamides
(therapeutic use)
- Sulfonic Acids
|